adherence and implementing interventions to ensure adequate adherence may provide an effective strategy to increase graft survival [7] .
As non-compliance is notoriously hard to evaluate [8, 9] , it has been suggested that tacrolimus blood-level variability be used to identify high-risk patients [10] . Indeed, several investigators have reported an association between high drug bloodlevel variability and reduced graft survival [11] [12] [13] [14] . Hence, monitoring blood-level variability may potentially be used as a convenient tool to identify high-risk patients.
A limitation of the published studies is the lack of data regarding the early post-transplant period. This limitation is due to the frequent dose adjustments and the impact of shortterm fluctuations in drug levels during this time frame. The exclusion of this early period in studies investigating drug-level variability leads to an underestimation of the effect of early drug-level variability. This may result in delayed detection of high-risk patients and delays timely interventions [7, 15] aimed at prevention of kidney graft damage.
High drug-level variability implies that patients are exposed to both high and low drug levels, while low levels are mostly associated with non-adherence [16] . Monitoring the patient for exposure to inadequately low drug levels may increase the specificity of high tacrolimus-level variability as a predictor of graft failure, thus allowing targeted interventions in a selected population.
In this study, we sought to evaluate whether calculating variability using a time-weighted method, which does not require stable dose or monitoring at regular interval, might enable the identification of high-risk patients early after transplantation and whether combining exposure to low tacrolimus drug levels provides an improved tool to identify these high-risk patients.
M A T E R I A L S A N D M E T H O D S

Patient recruitment
This is a single center retrospective study using the Rabin Medical Center (RMC) kidney transplant registry. We searched the RMC central computerized laboratory system for all patients who had tacrolimus drug levels evaluated between February 2000 and December 2013 and crossed them with the list of patients who had undergone kidney transplantation during the same time period.
We included in our study all adult patients (age >18 years) who had a functioning graft 6 months after transplantation. Patients with multi-organ transplantations, and those with incomplete baseline or outcome data were excluded. The study was approved by the RMC Institutional Review Board and was conducted according to the declaration of Helsinki and the declaration of Istanbul.
Immunosuppression. Maintenance immunosuppression included tacrolimus (Prograf, Astellas Pharma, Middelesex, UK) starting on post-operative day 1 at a dose of 0.15 mg/kg. Target 12-h trough levels for tacrolimus were 8-12 ng/mL during the first 3 months after transplantation and 5-8 ng/mL thereafter. Blood samples used for the determination of 12-h tacrolimus trough concentrations were collected at least once a week in the first month post-transplantation and at least once a month thereafter. Tacrolimus blood levels were determined by micro-particle enhancement immunoassay (IMx, Abbott Diagnostics, Abbott Park, IL, USA).
Anti-proliferative agents included mycophenolate mofetil (MMF; Cellcept, Roche Pharmaceuticals, Basel, Switzerland), started on post-operative day 1 at a dose of 2.0 g/day and reduced to 1.5 g/day on day 14 or mycophenolate sodium (Myfortic, Novartis Pharma, Basel, Switzerland), started on post-operative day 1 at a dose of 1440 mg/day and reduced to 1080 mg/day on day 14. All patients received perioperative intravenous corticosteroid therapy with methylprednisolone 500 mg on day 0, 250 mg on day 1 and 100 mg on day 2, and then oral prednisone 20 mg/day, tapered to 5 mg/day within 3 months. Induction therapy consisted of one of the following: anti-IL-2 receptor antagonist basiliximab (Simulect, Novartis Pharma, East Hanover, NJ, USA) on days 0 and 4 at a dosage of 20 mg intravenously or daclizumab (Zenapax, Roche Pharmaceuticals) 1 mg/kg on days 0 and 14 and rabbit antithymocyte globulin (thymoglobulin, Genzyme Corp., Cambridge, MA, USA) at a dosage of 1.0-1.5 mg/kg intravenously starting intra-operatively for 3 days for high-risk patients (re-transplant or positive panel reactive antibodies).
Rejection monitoring and treatment. Acute rejection was suspected when serum creatinine increased by >15% of the baseline value. Suspicion of acute rejection in the absence of other possible causes of acute kidney dysfunction promoted a kidney biopsy. Biopsy-confirmed acute rejection was diagnosed as Banff classification IA or more for cellular rejection and I or more for antibody-mediated rejection. Acute rejection was treated with either methylprednisolone 500 mg intravenously for 3 days for mild rejections or with thymoglobulin 1-1.5 mg/ kg for 3-5 days for more severe grades or for rejections not responsive to corticosteroids. Antibody-mediated acute rejection was treated with IVIG 500 mg/kg (Omrigam, Omrix, Ramat Gan, Israel) and plasmapheresis given three times on alternate days. For data analysis, an increase in serum creatinine was considered as rejection only when proved by biopsy. Estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and using creatinine values at 6 months after the transplantation.
Outcomes. The evaluated outcome was graft survival, defined as the composite endpoint of patient and graft survival. Graft loss was defined as return to dialysis or need for retransplantation. Return to dialysis data were obtained from the Israeli dialysis registration and re-transplantation from the transplantation registry. Death events were obtained using the Israeli population administration office.
Time-weighted coefficient of variability calculation
Tacrolimus blood level was determined by two assays during the study period. Until December 2010, microparticles enzyme immunoassay (IMx, Abbott Diagnostics) was used and was then replaced from January 2011 by chemiluminescent
Prior to the assay change, an extensive evaluation was done to show the equivalence of the two assays according to the Clinical & Laboratory Standard Institute protocol. The two assays were found to be in very good agreement (y ¼ 1.0428x -0.2295, R 2 ¼ 0.9773). For calculation of the time-weighted coefficient of variability (TWCV), we used all available tacrolimus blood levels during the first 6 months after transplantation. Time-weighted average (TWA) was calculated by the formula
where x i is the drug level for the interval, t i is the time interval and t is the total time of exposure. For the calculation of TWCV, we calculated the time-weighted standard deviation by the formula
and divided by the TWA to produce the TWCV. The calculation process is reported in detail in Supplementary file S1 and in Supplementary Figure S1 .
Statistical analysis. Continuous data are presented as mean 6 standard deviation or median, range, and dichotomous data as rate and percentage. Two-sample t-test and Mann-Whitney U-test were used for normally and non-normally distributed data, respectively. Differences in dichotomous variables were assessed by v 2 test. When numbers were small, the Fisher's exact test was used instead of the v 2 test. Kaplan-Meier survival curve was used for survival comparisons. The significance value of the difference between the curves was assessed by the log-rank test. Univariate and multivariate Cox proportional hazard model were used for univariate and multivariate analysis, respectively. The proportionality of the hazard was evaluated by adding the interaction for every variable with time and assessing for the null hypothesis.
The multivariate analysis was done using two models. First, we used stepwise backward regression model with P-value of 0.05 for inclusion and 0.1 for exclusion to adjust for the factors associated with the outcome (Model 1), and then we added to the model variables significantly associated with the evaluated variable (Model 2). Variables included in the analysis consisted of recipient characteristics: age, gender, pre-transplant diabetes mellitus, pre-transplant heart disease, infection with hepatitis C virus or hepatitis B virus, weight, last panel reactive antibodies results classified as positive or negative, and former transplantations. Donor features included donor type (living or deceased), age, gender and HLA mismatch between the donor and recipient. Transplantation-related variables included cold ischemia time, induction therapy, presence of delayed graft function, length of hospital stay and biopsy-confirmed acute rejections.
TWCV and length of hospitalization were log-transformed in order to normalize data distribution. Exposure to low drug levels was evaluated by multiplying the time interval of exposure by the difference between the low drug value (e.g. values <5 ng/ mL) and 5 ng/mL value above 1 ng*day/mL was considered positive. Exposure to high drug levels was evaluated in a similar manner using the cutoff of 15 ng/mL.
R E S U L T S
Patient population
A total of 1126 patients underwent kidney transplantation in our center between 1 January 2000 and 29 September 2013 and were treated with tacrolimus. Of these patients, 45 (4%) had non-functioning graft at 180 days, 49 (4.4%) were switched to cyclosporine or sirolimus, 84 (7.5%) had fewer than eight tacrolimus values available for analysis during the first 6 months and 145 (12.9%) patients had interval of >60 days between adjacent drug values. The characteristics of the 803 (71.3%) patients included in the study are presented in Table 1 . The number of drug-level measurement values was 20.7 6 6.5 (20, , the mean value of the longest interval between tacrolimus level measurements was 33 6 10.2 (33, 11-60) days and the TWA for drug level at 180 days was 9.9 6 1.5 (9.8, 3.5-15.6) ng/mL.
Variables associated with TWCV
At 180 days, the TWCV was 34.8 6 21.3% (31.1%, 6.25-293.8%). Patients within the high tertile group of TWCV were more likely to have diabetes mellitus and more drug-level measurements. Table 1 shows comparison data between groups.
TWCV and graft survival
During a median follow-up time of 3.7 (0.5-12.9) years, 98 events occurred (49 events of graft failure and 49 events of death with functioning graft). Patients within the high tertile of TWCV had inferior graft survival compared with the other tertiles by Kaplan-Meier survival model (P ¼ 0.002, Figure 1 ) and by univariate Cox proportional hazard model [hazard ratio (HR) 1.83, 95% confidence interval (CI) 1.23-2.73, P ¼ 0.003]. The association remained significant after adjustment for other variables associated with the outcome (Model 1) and the addition of variables associated with high coefficient of variability (Model 2) (HR 2.14, 95% CI 1.42-3.23, P ¼ 0.001 for Model 1 and HR 2.07, 95% CI 1.36-3.15, P ¼ 0.001 for Model 2). Higher TWCV was also associated with increased graft loss when introduced as continuous variables using univariate (HR 7.35 per log TWCV, 95% CI 3.64-15.53, P < 0.001) and adjusted models (HR 7.74, 95% CI 3.66-16.46, P ¼ 0.007 for Model 1 and HR 7.94, 95% CI 3.36-18.98, P ¼ 0.011 for Model 2). Supplementary Figure S2 presents the HRs associated with high coefficient of variability.
Effect of exposure to low drug level
In order to evaluate the association between high TWCV and exposure to low or high drug level, we evaluated the interaction between TWCV and exposure to low or high drug levels and graft survival. While the interaction of high variability with exposure to low drug level was significantly associated with graft survival (P < 0.001), the interaction with exposure to high drug . In order to further evaluate the interaction, we divided the patients into four groups: low TWCV and no exposure to low drug levels, low variability with exposure to low drug levels (<5 ng/mL), high TWCV (top tertile) without exposure to low drug levels and the combination of high TWCV and exposure to low drug levels (combination group). As can be seen in Figure 2 , only the group with high TWCV and low drug levels (the combination group) had significantly reduced graft survival, compared with all other groups (P < 0.001). The characteristics of that group are presented in Table 2 . By univariate Cox proportional hazard ratio, the combination group had increased hazard of graft failure compared with the other groups pooled together (HR 2.76, 95% CI 1.8-4.23, P < 0.001). After adjusting for other variables associated with the outcome, and the addition of covariates associated Figure S2) . We performed several sensitivity analyses to support these results. Analyzing the association between the combination group and death-censored graft survival showed increased hazard of graft failure by univariate (HR 3.14, 95% CI 1.74-3.67, P < 0.001) and multivariate analyses (HR 3.74, 95% CI 1.99-7.03, P < 0.001, Model 1). We also evaluated the association between graft survival (including death) and the combination group excluding 13 patients with graft survival of <1 year. The combination group was associated with increased late graft loss by univariate and multivariate analyses (HR 2.43, 95% CI 1.51-3.83, P < 0.001 and HR 2.57, 95% CI 1.57-4.19, P < 0.001, respectively). Finally, we evaluated the outcome in 593 patients who had >15 measurements available for analysis. The combination group had increased graft loss by univariate and multivariate adjusted model analyses (HR 2.65, 95% CI 1.6-4.37, P < 0.001 and HR 2.63, 95% CI 1.59-4.36, P < 0.001, respectively).
D I S C U S S I O N
In this study, we evaluated the association between TWCV in the early post-transplant period and graft survival in 803 patients. There was a significant association between high coefficient of variability and reduced graft survival, both by univariate and by adjusted models. As variability is associated with exposure to both low and high drug levels, we further evaluated the effect of exposure to low tacrolimus blood levels. The group of patients in the highest tertile of TWCV who were exposed to tacrolimus levels <5 ng/mL had a significantly increased risk, while patients not exposed to low drug levels did not. These results imply that the combination of high TWCV and exposure to low drug levels can identify high-risk patients.
The association between variability of immunosuppressive drug levels and graft outcome was explored in several studies. Borra et al. evaluated in his seminal work variability in tacrolimus and MMF clearance in 297 patients during the second half of the first post-transplantation year. After a median follow-up period of about 5 years, 34 patients reached the end point of graft loss. Variability in tacrolimus clearance was associated with increased graft loss, while MMF clearance variability had no effect on this outcome [13] . Sapir-Pichhadze et al. evaluated the effect of tacrolimus variability, defined as standard deviation from the first year until the end of follow-up, on a composite outcome of late allograft rejection, transplant glomerulopathy and total graft loss including mortality. After analyzing data from 356 patients in a time-dependent fashion, each unit of tacrolimus blood-level standard deviation was associated with a 27% increase in in this composite outcome [14] . Another recent report also found an association between variability during the 3-to 12-month period and graft survival in 394 patients [17] . Finally, data regarding a large contemporary cohort of 808 patients were recently reported by Shuker et al. [18] . In this cohort, high variability was associated with increased hazard of composite end point consisting of graft loss, late biopsy-proven rejection, transplant glomerulopathy or doubling of serum creatinine. It should be noted that in addition to high variability, low tacrolimus blood level at 1 year was associated with worse graft outcome. In addition to corroborating the data from the former studies in a large independent cohort, our study adds three very important findings to the previously mentioned studies. First, the main outcome of this study was graft survival not censored for death. As mortality might be affected by reduced kidney function and risks of infections and severe metabolic disorders due to over immunosuppression, we hypothesized that this outcome is more relevant. Second, we used TWA for calculation of variability. This method greatly reduces the effect of short periods of multiple measurements, which are typical of acute events, on the calculated variability value. Such events as hospitalizations, infections and rejections [19, 20] might influence graft survival in a variability-independent manner and hence might serve as possible confounding factors. Using this calculation method also enabled us to include the immediate post-transplant period in our analysis. This period is characterized by unstable drug dose and variable levels and has a tremendous effect on long-term outcome. It should be noted that the coefficient of variability in this study was higher than in previous studies. This difference might be attributed to the inclusion of the early post-transplantation period. During this period, the target drug blood level is not fixed and other medications and diet are changed frequently, so increased variability is expected.
Increased variability in immunosuppressive therapy is associated with exposure to low drug levels and the risk of immunological injury [3, 4] , as well as exposure to high drug levels and the risk of drug toxicity [21, 22] . We therefore evaluated the interaction between exposure to high and low drug levels and variability. Our results show a very clear interaction between variability and exposure to tacrolimus blood levels <5 ng/mL and no interaction with exposure to high drug levels. This finding may be explained by the ability of this combination to identify patients with high risk of non-adherence, which represents a known risk factor for graft loss [23, 24] . These results are also in agreement with the results reported by Shuker et al., which found that lower tacrolimus drug levels are associated with poor graft survival [18] .
Variability in drug blood level can be affected by many factors, including drug absorption, drug metabolism, drug formulation, concurrent medications, monitoring practice and compliance [25] . Variation in drug absorption is due to concomitant food ingestion [26] , change in gut flora and acute or chronic diarrheal illness [27, 28] , and can be prevented by taking the drug without food, frequent monitoring and adjustment during acute or chronic diarrhea. Variation in metabolism results from interaction with food [26, 29] and medications [30] , and can be prevented by careful patient instruction. Using a once-daily formulation of tacrolimus was shown to reduce variability [31, 32] . However, the effects of generic formulation, variable drug dosing and monitoring practice on drug-level variability have not been evaluated and remain unclear.
Non-adherence to drug therapy is probably the most important source of drug-level variability [33] . Several studies found significant correlation between non-adherence and acute cellular and humoral rejections [34] , DSA appearance [35] and graft loss [6, 36, 37] . As non-adherence to medical therapy is notoriously difficult to evaluate [6, 9] , it has been suggested that tacrolimus-level variability might serve as a monitoring tool to help identify patients at risk [10] . Our results define a subgroup of patients with exposure to both high variability and low drug level that may be identified early in the post-transplant period and targeted by specific intervention. This subgroup, which composed 16% of our population, had an adjusted risk of about 2.5 for graft loss. Increasing compliance, as well as identifying and addressing other sources of variability and inadequate drug exposure, might reduce the excessive risk.
The reason that patients with the combination of exposure to low tacrolimus levels and high variability had significantly reduced graft survival as compared with the low tacrolimus blood levels without high variability is unclear. Several hypotheses may be put forward. One possible explanation is that this combination can better identify patients with low compliance, since these patients tend to avoid drug doses and are exposed to more episodes of low drug level [38] , as compared with patients with relatively stable low drug blood levels. In addition, these patients may possibly be exposed to episodes of undocumented very low drug levels. These episodes may trigger the humoral immune system, thus leading to chronic antibody-mediated rejection, which is the most important cause for graft loss [39] . Finally, sharp fluctuations between immunosuppressed and immunocompetent states may trigger an anti-graft immune response, as compared with gradual reductions in immunosuppression.
Although this study represents a large contemporary cohort with adequate follow-up time, it has several limitations. First, since this study is single-centered, it may not be applied to a broader transplant population. Another potential limitation is the retrospective nature of the trial, though the use of a prospective registry of clinical and laboratory data from a central computerized data system limits potential biases. The most important limitation of the study is the lack of evaluation of compliance, which is the most important factor affecting drug level variability and, probably, graft survival. Despite the lack of compliance data, it is reasonable to assume that high drug level variability reflects non-compliance with immunosuppressive therapy, thus providing tools for caregivers to identify a patient population at high risk for graft loss.
Further studies are needed to establish the association between high variability and non-compliance and evaluate the effectiveness of interventions to reduce non-compliance in this group of high-risk patients.
In conclusion, the combination of high drug level variability and exposure to tacrolimus levels <5 ng/ml is associated with high risk of graft loss. Such patients should be closely evaluated for non-adherence and other sources of increased blood-level variability. Timely intervention in this population may prevent early graft loss.
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